103 related articles for article (PubMed ID: 1621201)
21. Shrinkage effect of gonadotropin releasing hormone agonist treatment on uterine leiomyomas and t(12;14).
Takahashi K; Kawamura N; Ishiko O; Ogita S
Int J Oncol; 2002 Feb; 20(2):279-83. PubMed ID: 11788889
[TBL] [Abstract][Full Text] [Related]
22. Hormonal therapy before surgical treatment for uterine leiomyomas.
Moghissi KS
Surg Gynecol Obstet; 1991 Jun; 172(6):497-502. PubMed ID: 1827931
[TBL] [Abstract][Full Text] [Related]
23. Obesity and GnRH action. Report of a case with contribution by peripherally derived estrogens.
Hansen LM; Batzer FR; Corson SL; Bello S
J Reprod Med; 1997 Apr; 42(4):247-50. PubMed ID: 9131500
[TBL] [Abstract][Full Text] [Related]
24. GnRH agonists before surgery for uterine leiomyomas. A review.
Crosignani PG; Vercellini P; Meschìa M; Oldani S; Bramante T
J Reprod Med; 1996 Jun; 41(6):415-21. PubMed ID: 8799917
[TBL] [Abstract][Full Text] [Related]
25. Leuprolide acetate treatment and myoma arterial size.
Rutgers JL; Spong CY; Sinow R; Heiner J
Obstet Gynecol; 1995 Sep; 86(3):386-8. PubMed ID: 7651647
[TBL] [Abstract][Full Text] [Related]
26. A placebo-controlled trial of a depot gonadotropin-releasing hormone analogue (leuprolide) in the treatment of uterine leiomyomata.
Schlaff WD; Zerhouni EA; Huth JA; Chen J; Damewood MD; Rock JA
Obstet Gynecol; 1989 Dec; 74(6):856-62. PubMed ID: 2511532
[TBL] [Abstract][Full Text] [Related]
27. Influence on hormone levels, lipid metabolism and reversibility of endocrinological changes after leuprorelin acetate depot therapy.
Bühler K; Winkler U; Schindler AE
Clin Ther; 1992; 14 Suppl A():104-13. PubMed ID: 1606590
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of ipriflavone in preventing adverse effects of leuprolide.
Somekawa Y; Chiguchi M; Ishibashi T; Wakana K; Aso T
J Clin Endocrinol Metab; 2001 Jul; 86(7):3202-6. PubMed ID: 11443189
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical detection of insulin-like growth factor type I receptor and uterine volume changes in gonadotropin-releasing hormone analog-treated uterine leiomyomas.
Di Lieto A; Iannotti F; De Falco M; Staibano S; Pollio F; Ciociola F; De Rosa G
Am J Obstet Gynecol; 2003 Mar; 188(3):702-6. PubMed ID: 12634644
[TBL] [Abstract][Full Text] [Related]
30. Estriol add-back therapy in the long-acting gonadotropin-releasing hormone agonist treatment of uterine leiomyomata.
Nakayama H; Yano T; Sagara Y; Kikuchi A; Ando K; Wang Y; Watanabe M; Matsumi H; Osuga Y; Momoeda M; Taketani Y
Gynecol Endocrinol; 1999 Dec; 13(6):382-9. PubMed ID: 10685331
[TBL] [Abstract][Full Text] [Related]
31. [Usefulness of GnRH agonists in preoperative treatment of complicated uterine myomata].
Campusano C; Zapata R; Bianchi M; Badia JI; Arteaga E
Rev Chil Obstet Ginecol; 1993; 58(2):150-4. PubMed ID: 8209044
[TBL] [Abstract][Full Text] [Related]
32. Preoperative treatment of uterine leiomyomas: clinical findings and expression of transforming growth factor-beta3 and connective tissue growth factor.
De Falco M; Staibano S; D'Armiento FP; Mascolo M; Salvatore G; Busiello A; Carbone IF; Pollio F; Di Lieto A
J Soc Gynecol Investig; 2006 May; 13(4):297-303. PubMed ID: 16697947
[TBL] [Abstract][Full Text] [Related]
33. Tibolone reverses the cognitive effects caused by leuprolide acetate administration, improving mood and quality of life in patients with symptomatic uterine leiomyomas.
Palomba S; Orio F; Falbo A; Oppedisano R; Tolino A; Zullo F
Fertil Steril; 2008 Jul; 90(1):165-73. PubMed ID: 18001721
[TBL] [Abstract][Full Text] [Related]
34. Leuprolide acetate depot for the treatment of uterine leiomyomas. Changes in bone density, uterine volume and uterine vascular resistive index.
Rivlin ME; Patel RB; Hess LW; Hess DB; Meeks GR
J Reprod Med; 1994 Sep; 39(9):663-6. PubMed ID: 7807474
[TBL] [Abstract][Full Text] [Related]
35. Effects of gonadotropin-releasing hormone analog treatment on skin condition.
Osuga Y; Yano T; Kugu K; Koga K; Fukuoka K; Matsumi H; Wada O; Kikuchi A; Tsutsumi O; Taketani Y
Gynecol Endocrinol; 2002 Feb; 16(1):57-61. PubMed ID: 11915583
[TBL] [Abstract][Full Text] [Related]
36. A randomized trial evaluating leuprolide acetate before hysterectomy as treatment for leiomyomas.
Stovall TG; Ling FW; Henry LC; Woodruff MR
Am J Obstet Gynecol; 1991 Jun; 164(6 Pt 1):1420-3; discussion 1423-5. PubMed ID: 1904681
[TBL] [Abstract][Full Text] [Related]
37. Hyalinization and cellular changes in uterine leiomyomata after gonadotropin releasing hormone agonist therapy.
Cohen D; Mazur MT; Jozefczyk MA; Badawy SZ
J Reprod Med; 1994 May; 39(5):377-80. PubMed ID: 7520497
[TBL] [Abstract][Full Text] [Related]
38. A prospective randomized study to evaluate leuprolide acetate treatment before laparoscopic myomectomy: efficacy and ultrasonographic predictors.
Zullo F; Pellicano M; De Stefano R; Zupi E; Mastrantonio P
Am J Obstet Gynecol; 1998 Jan; 178(1 Pt 1):108-12. PubMed ID: 9465812
[TBL] [Abstract][Full Text] [Related]
39. GnRH agonist and iron versus placebo and iron in the anemic patient before surgery for leiomyomas: a randomized controlled trial. Leuprolide Acetate Study Group.
Stovall TG; Muneyyirci-Delale O; Summitt RL; Scialli AR
Obstet Gynecol; 1995 Jul; 86(1):65-71. PubMed ID: 7784025
[TBL] [Abstract][Full Text] [Related]
40. Relationship between platelet-derived growth factor expression in leiomyomas and uterine volume changes after gonadotropin-releasing hormone agonist treatment.
Di Lieto A; De Rosa G; De Falco M; Iannotti F; Staibano S; Pollio F; Scaramellino M; Salvatore G
Hum Pathol; 2002 Feb; 33(2):220-4. PubMed ID: 11957148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
